Julie Aziz
Nurse Practitioner · Liverpool, NYNPI 1104998566
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,109 and has fallen 63.4% since, to $406 in 2025. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$769
- Biogen$311
- Teva Pharmaceuticals USA, Inc.$167
- Mallinckrodt Hospital Products Inc.$153
- Genentech USA, Inc.$145
- Sanofi$136
- plus $2K from 35 others
What the payments were for
- Consulting fees$602%
- Food & beverage$3,16096%
- Education$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $769 |
| Biogen | 19 | $311 |
| Teva Pharmaceuticals USA, Inc. | 8 | $167 |
| Mallinckrodt Hospital Products Inc. | 3 | $153 |
| Genentech USA, Inc. | 10 | $145 |
| Sanofi | 6 | $136 |
| Amneal Pharmaceuticals LLC | 5 | $114 |
| EMD Serono, Inc. | 4 | $99 |
| Livanova USA, Inc. | 2 | $97 |
| TG Therapeutics, Inc. | 3 | $93 |
| Neurocrine Biosciences, Inc. | 4 | $90 |
| Pfizer | 4 | $87 |
| Bristol Myers Squibb | 4 | $86 |
| SK Life Science, Inc. | 4 | $80 |
| MDD US Operations, LLC | 4 | $76 |
| Acadia Pharmaceuticals Inc | 5 | $75 |
| UCB, Inc. | 3 | $64 |
| Abbott | 3 | $59 |
| AstraZeneca | 3 | $56 |
| Impel Pharmaceuticals Inc. | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Novartis | 2 | $37 |
| Johnson & Johnson | 1 | $31 |
| Eisai Inc. | 2 | $30 |
| Lilly USA, LLC | 2 | $28 |
| Acorda Therapeutics, Inc | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Upsher-smith Laboratories LLC | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Argenx US, Inc. | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Merz Pharmaceuticals, LLC | 1 | $14 |
| Amgen | 1 | $13 |
| GE HealthCare | 2 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$100
How this compares
$3,279 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 28 | $170,003 |
| NuplazidPimavanserin Tartrate | 21 | $134,527 |
| Teriflunomide | 34 | $114,510 |
| MysolinePrimidone | 14 | $114,445 |
| IngrezzaValbenazine Tosylate | 12 | $97,179 |
| Glatiramer Acetate | 39 | $63,776 |
| TopamaxTopiramate | 14 | $37,388 |
| GlatopaGlatiramer Acetate | 14 | $29,121 |
| OngentysOpicapone | 14 | $11,302 |
| Rasagiline Mesylate | 35 | $8,504 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $8,492 |
| Dalfampridine ErDalfampridine | 16 | $6,983 |
| Entacapone | 12 | $2,788 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 45 | $2,593 |
| Selegiline Hcl | 21 | $2,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $167 | $170,00328 claims |
| Acadia Pharmaceuticals IncNuplazid | $75 | $134,52721 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $90 | $108,48126 claims |
| Upsher-smith Laboratories LLCTopiramate | $24 | $72876 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Liverpool
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
- Kelly WilmarthJohnson City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.